Guillermina FERRO FLORES,Blanca Eli OCAMPO GARCÍA,Clara Leticia SANTOS CUEVAS,Myrna Alejandra LUNA GUTIÉRREZ,Erika Patricia AZORÍN VEGA,Nallely Patricia JIMÉNEZ MANCILLA
申请号：
US16310744
公开号：
US20190343970A1
申请日:
2017.06.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal 99mTc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical 99mTc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo, the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA.
